Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Walid Fayad is active.

Publication


Featured researches published by Walid Fayad.


Nature Communications | 2014

Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments.

Xiaonan Zhang; Mårten Fryknäs; Emma Hernlund; Walid Fayad; Angelo De Milito; Maria Hägg Olofsson; Vladimir Gogvadze; Long H. Dang; Sven Påhlman; Leoni Kunz Schughart; Linda Rickardson; Padraig D’Arcy; Joachim Gullbo; Peter Nygren; Rolf Larsson; Stig Linder

Abnormal vascularization of solid tumours results in the development of microenvironments deprived of oxygen and nutrients that harbour slowly growing and metabolically stressed cells. Such cells display enhanced resistance to standard chemotherapeutic agents and repopulate tumours after therapy. Here we identify the small molecule VLX600 as a drug that is preferentially active against quiescent cells in colon cancer 3-D microtissues. The anticancer activity is associated with reduced mitochondrial respiration, leading to bioenergetic catastrophe and tumour cell death. VLX600 shows enhanced cytotoxic activity under conditions of nutrient starvation. Importantly, VLX600 displays tumour growth inhibition in vivo. Our findings suggest that tumour cells in metabolically compromised microenvironments have a limited ability to respond to decreased mitochondrial function, and suggest a strategy for targeting the quiescent populations of tumour cells for improved cancer treatment.


Journal of Biomolecular Screening | 2007

Screening for Compounds That Induce Apoptosis of Cancer Cells Grown as Multicellular Spheroids

Richard Herrmann; Walid Fayad; Stephan Schwarz; Maria Berndtsson; Stig Linder

Screening and initial characterization of anticancer drugs are typically performed using monolayer cultures of tumor cells. It is well established that such monolayer cultures do not represent the characteristics of 3-dimensional solid tumors. The multicellular tumor spheroid model is of intermediate complexity between in vivo tumors and in vitro monolayer cultures and would be more suitable for drug screening. The authors describe a procedure in which multicellular spheroids are used to screen for compounds that induce tumor cell apoptosis. Multicellular spheroids were generated in 96-well plates, and apoptosis was determined using the M30-Apoptosense ® enzyme-linked immunosorbent assay method. A Z′ factor of approximately 0.5 was observed for HCT116 colon carcinoma spheroids using staurosporine to induce apoptosis. This procedure is attractive for secondary screening of hits from larger cell-based screens. (Journal of Biomolecular Screening 2008:1-8)


PLOS ONE | 2009

Identification of a Novel Topoisomerase Inhibitor Effective in Cells Overexpressing Drug Efflux Transporters

Walid Fayad; Mårten Fryknäs; Slavica Brnjic; Maria Hägg Olofsson; Rolf Larsson; Stig Linder

Background Natural product structures have high chemical diversity and are attractive as lead structures for discovery of new drugs. One of the disease areas where natural products are most frequently used as therapeutics is oncology. Method and Findings A library of natural products (NCI Natural Product set) was screened for compounds that induce apoptosis of HCT116 colon carcinoma cells using an assay that measures an endogenous caspase-cleavage product. One of the apoptosis-inducing compounds identified in the screen was thaspine (taspine), an alkaloid from the South American tree Croton lechleri. The cortex of this tree is used for medicinal purposes by tribes in the Amazonas basin. Thaspine was found to induce conformational activation of the pro-apoptotic proteins Bak and Bax, mitochondrial cytochrome c release and mitochondrial membrane permeabilization in HCT116 cells. Analysis of the gene expression signature of thaspine-treated cells suggested that thaspine is a topoisomerase inhibitor. Inhibition of both topoisomerase I and II was observed using in vitro assays, and thaspine was found to have a reduced cytotoxic effect on a cell line with a mutated topoisomerase II enzyme. Interestingly, in contrast to the topoisomerase II inhibitors doxorubicin, etoposide and mitoxantrone, thaspine was cytotoxic to cell lines overexpressing the PgP or MRP drug efflux transporters. We finally show that thaspine induces wide-spread apoptosis in colon carcinoma multicellular spheroids and that apoptosis is induced in two xenograft mouse models in vivo. Conclusions The alkaloid thaspine from the cortex of Croton lechleri is a dual topoisomerase inhibitor effective in cells overexpressing drug efflux transporters and induces wide-spread apoptosis in multicellular spheroids.


Chemical Biology & Drug Design | 2011

Identification of Agents that Induce Apoptosis of Multicellular Tumour Spheroids: Enrichment for Mitotic Inhibitors with Hydrophobic Properties

Walid Fayad; Linda Rickardson; Caroline Haglund; Maria Hägg Olofsson; Padraig D’Arcy; Rolf Larsson; Stig Linder; Mårten Fryknäs

Cell‐based anticancer drug screening generally utilizes rapidly proliferating tumour cells grown as monolayer cultures. Hit compounds from such screens are not necessarily effective on hypoxic and slowly proliferating cells in 3‐D tumour tissue. The aim of this study was to examine the potential usefulness of 3‐D cultured tumour cells for anticancer drug screening. We used colon carcinoma multicellular spheroids containing hypoxic and quiescent cells in core areas for this purpose. Three libraries (∼11 000 compounds) were screened using antiproliferative activity and/or apoptosis as end‐points. Screening of monolayer and spheroid cultures was found to identify different sets of hit compounds. Spheroid screening enriched for hydrophobic compounds: median XLogP values of 4.3 and 4.4 were observed for the hits in two independent screening campaigns. Mechanistic analysis revealed that the majority of spheroid screening hits were microtubuli inhibitors. One of these inhibitors was examined in detail and found to be effective against non‐dividing cells in the hypoxic centres of spheroids. Spheroid screening represents a conceptually new strategy for anticancer drug discovery. Our findings have implications for drug library design and hit selection in projects aimed to develop drugs for the treatment of solid tumours.


Cancer Science | 2011

Novel activity of acriflavine against colorectal cancer tumor cells

Saadia Bashir Hassan; Daniel Laryea; Haile Mahteme; Jenny Felth; Mårten Fryknäs; Walid Fayad; Stig Linder; Linda Rickardson; Joachim Gullbo; Wilhelm Graf; Lars Påhlman; Bengt Glimelius; Rolf Larsson; Peter Nygren

A high‐throughput screen of the cytotoxic activity of 2000 molecules from a commercial library in three human colon cancer cell lines and two normal cell types identified the acridine acriflavin to be a colorectal cancer (CRC) active drug. Acriflavine was active in cell spheroids, indicating good drug penetration and activity against hypoxic cells. In a validation step based on primary cultures of patient tumor cells, acriflavine was found to be more active against CRC than ovarian cancer and chronic lymphocytic leukemia. This contrasted to the activity pattern of the CRC active standard drugs 5‐fluorouracil, irinotecan and oxaliplatin. Mechanistic studies indicated acriflavine to be a dual topoisomerase I and II inhibitor. In conclusion, the strategy used seems promising for identification of new diagnosis‐specific cancer drugs. (Cancer Sci 2011; 102: 2206–2213)


International Journal of Cancer | 2009

Restriction of cisplatin induction of acute apoptosis to a subpopulation of cells in a three-dimensional carcinoma culture model

Walid Fayad; Slavica Brnjic; Daniel Berglind; Susanna Blixt; Maria C. Shoshan; Maria Berndtsson; Maria Hägg Olofsson; Stig Linder

Cisplatin is a clinically important chemotherapeutical agent used to treat epithelial malignancies. High concentrations (20–100 μM) of cisplatin have been used in numerous studies to induce apoptosis of carcinoma cells grown in monolayer culture over 24–48 hr. These conditions may not be relevant to 3‐D tumor tissue in vivo and the importance of apoptosis for tumor response is controversial. We here studied the effects of cisplatin on a 3‐D colon carcinoma in vitro model (multicellular spheroids). Cisplatin at a dose of 40 μM induced active caspase‐3 preferentially in the peripheral 30 μm cell layer of spheroids, mainly during late stages (72–96 hr). The p53 response to cisplatin was also largely confined to peripheral cell layers. Despite the use of a high cisplatin concentration, a significant fraction of the cells in the spheroids survived treatment. A high proportion of surviving cells stained positive for β‐galactosidase, a marker of premature senescence. Cells growth‐arrested by cisplatin treatment showed a higher spontaneous cell death rate than untreated proliferating cells. We propose that acute apoptosis is of minor significance for the overall response of carcinoma cells to cisplatin treatment.


Cancer Biomarkers | 2009

Specific demonstration of drug-induced tumour cell apoptosis in human xenografts models using a plasma biomarker

M Hägg Olofsson; Jeffrey Cummings; Walid Fayad; Slavica Brnjic; Richard Herrmann; Maria Berndtsson; Cassandra L Hodgkinson; Emma Dean; Rajesh Odedra; R. Wilkinson; Kirsten E. Mundt; M Busk; Caroline Dive; Stig Linder

Pharmacodynamic (PD) assays should be used before advancing new drugs to clinical trials. Most PD assays measure the response to drugs in tissue, a procedure which requires tissue biopsies. The M30-Apoptosense ELISA is a PD biomarker assay for the quantitative determination of caspase-cleaved cytokeratin 18 (CK18) released from apoptotic carcinoma cells into blood. We here demonstrate that whereas the M30-Apoptosense ELISA assay detects human caspase-cleaved CK18, the mouse and rat CK18 caspase cleavage products are detected with low affinity. The M30-Apoptosense ELISA therefore facilitates the determination of drug-induced apoptosis in human tumour xenografts in rodents using plasma samples, largely independently from host toxicity. Increases of caspase-cleaved CK18 were observed in plasma from different carcinoma xenograft models in response to anticancer drugs. The appearance caspase-cleaved CK18 in plasma was found to reflect formation of the caspase-cleaved epitope in FaDu head-neck carcinomas and in cultured cells. The M30-Apoptosense assay allows determination of tumour response in blood from xenograft models and from patients, providing a powerful tool for translational studies of anticancer drugs.


European Journal of Cancer | 2012

The phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 is effective in inhibiting regrowth of tumour cells after cytotoxic therapy

Emma Hernlund; Maria Hägg Olofsson; Walid Fayad; Mårten Fryknäs; Karolina Lesiak-Mieczkowska; Xiaonan Zhang; Slavica Brnjic; Vivien Schmidt; Padraig D’Arcy; Tobias Sjöblom; Angelo De Milito; Rolf Larsson; Stig Linder

PURPOSE Regrowth of tumour cells between cycles of chemotherapy is a significant clinical problem. Treatment strategies where antiproliferative agents are used to inhibit tumour regrowth between chemotherapy cycles are attractive, but such strategies are difficult to test using conventional monolayer culture systems. METHODS We used the in vitro tumour spheroid model to study regrowth of 3-D colon carcinoma tissue after cytotoxic therapy. Colon carcinoma cells with wild-type or mutant phosphatidyl inositol 3-kinase catalytic subunit (PI3KCA) or KRAS alleles were allowed to form multicellular spheroids and the effects of different pharmacological compounds were studied after sectioning and staining for relevant markers of cell proliferation and apoptosis. RESULTS Studies using colon cancer cells with gene disruptions suggested that the phosphoinositide 3-kinase (PI3K)-mammalian target of rapamycin (mTOR) pathway was essential for proliferation in 3-D culture. The dual PI3K-mTOR inhibitor NVP-BEZ235, currently in clinical trials, was found to inhibit phosphorylation of the mTOR target 4EBP1 in 3-D cultured cells. The ability of NVP-BEZ235 to inhibit tumour cell proliferation and to induce apoptosis was markedly more pronounced in 3-D cultures compared to monolayer cultures. It was subsequently found that NVP-BEZ235 was effective in inhibiting regrowth of 3-D cultured cells after treatment with two cytotoxic inhibitors of the ubiquitin-proteasome system (UPS), methyl-13-hydroxy-15-oxokaurenoate (MHOK) and bortezomib (Velcade®). CONCLUSIONS The dual PI3K-mTOR inhibitor NVP-BEZ235 was found to reduce cell proliferation and to induce apoptosis in 3-D cultured colon carcinoma cells, NVP-BEZ235 is a promising candidate for use in sequential treatment modalities together with cytotoxic drugs to reduce the cell mass of solid tumours.


Medicinal Chemistry Research | 2016

Anticancer activity of some [1,2,4]triazepino[2,3-a] quinazoline derivatives: monolayer and multicellular spheroids in vitro models

Hanem M. Awad; Walid Fayad; Salwa M. El-Hallouty; Thoraya A. Farghaly; Mohamad M. Abdallah

In this study, five derivatives of triazepino[2,3-a] quinazoline-2,7(1H)-dione were synthesized and their anticancer activities were investigated both in two-dimensional-monolayer and three-dimensional-multicellular spheroids cancer models. All the five compounds showed very high anticancer activities against the 11 cancer cell types that have been investigated in the monolayer model. Comparing the results of both monolayer and multicellular spheroids models of the anticancer activity of these five compounds, we can conclude that the meta-methyl derivative induced its anticancer activity through apoptosis to give the best results in the monolayer model. However, in the multicellular spheroids model its apoptotic activity induced moderate anticancer activity (64 % cytotoxicity). On the other hand, both two nitro-derivatives either in meta-position or para-position, did not show potent pro-apoptotic activities toward the monolayer model but showed very high cytotoxic activity toward the multicellular spheroids model (100 %). These results reveal that the cell death mechanism induced by both nitro-compounds is exerted via other path than the apoptosis. Interestingly, all the tested compounds were generally safe to normal cells spheroids when tested at the same concentration.


journal of Cancer Therapeutics and Research | 2013

Massive induction of apoptosis of multicellular tumor spheroids by a novel compound with a calmodulin inhibitor-like mechanism

Chitralekha Mohanty; Walid Fayad; Maria Hägg Olofsson; Rolf Larsson; Angelo De Milito; Mårten Fryknäs; Stig Linder

Abstract Background: A number of anticancer drug candidates have been identified by cell-based screens utilizing tumor cells grown in monolayer culture. Since such cultures are poor models of 3-D tumor

Collaboration


Dive into the Walid Fayad's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge